EUVIMEDEUVIMED entdecken
Crossref

Pharmacokinetic Studies of a Novel c‐Met Targeting PROTAC Drug Candidate Using UPLC‐MS/MS Quantification Methods

Yan Gao iD, Xinyu Li, Chao Xin, Xiangdong Su, Lianfeng Ai, Jiangmeng Zeng, Shilin Liu, Jinxu Wang

Biopharmaceutics & Drug Disposition · 2026

DOI: 10.1002/bdd.70022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biopharmaceutics & Drug Disposition, 2026. Verfasst von Yan Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-met, Antineoplastic Agents. Die Arbeit nennt 23 Literaturangaben. Gefördert von: Shijiazhuang high-level scientific and technological innovation and entrepreneurial talent program, Key technologies for ubiquitin-mediated protein-targeted degradation and the development of new drugs for tissue-targeted protein-targeted degradation in Class….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

TPD354 is a novel Proteolysis Targeting Chimera (PROTAC) drug candidate that targets the degradation of cellular mesenchymal‐epithelial transforming factor (c‐Met) kinase. It showed significant therapeutic efficacy in vivo gastric cancer models. We have developed a robust and sensitive analytical method for evaluating the pharmacokinetic properties of TPD354, using ultra‐performance liquid chromatography coupled with tandem mass spectrometry (UPLC‐MS/MS) to quantify drug concentrations in diverse biological matrices. The method was validated and applied to pharmacokinetic studies of the compound. The method exhibited excellent specificity in the linear range of 6.995–6995.000 ng/mL. Moreover, the method met or exceeded established criteria for precision, accuracy, recovery, and matrix effects, ensuring its suitability for in vivo analysis. The method was applied to the study of drug pharmacokinetics in rats, stability in different types of liver microsomes, and protein binding in plasma of different species. Our studies have demonstrated that TPD354 exhibits metabolic stability in liver microsomes and is characterized by high plasma protein binding, with a half‐life of approximately 16 h in rats. These findings suggest that TPD354 is a promising PROTAC drug candidate, with strong potential for the treatment of c‐Met targeted cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-metAntineoplastic AgentsAnimalsProteolysis Targeting ChimeraTandem Mass SpectrometryMicrosomes, LiverRats, Sprague-DawleyMaleRatsChromatography, High Pressure LiquidHumansProtein BindingHalf-LifeLiquid Chromatography-Mass Spectrometry

Stichwörter der Autor:innen

PROTACUPLC‐MS/MSc‐Met degradationpharmacokinetics

Substanzen

Proteolysis Targeting ChimeraProto-Oncogene Proteins c-metAntineoplastic Agents

Autor:innen und Institutionen

  • College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology, Shijiazhuang, China.
  • TPD Pharmaceutical Technology (SJZ) Co. Ltd, Shijiazhuang, China.
  • Shijiazhuang Customs Technology Center, Shijiazhuang, China.

ORCID-Profile: Yan Gao

Förderung

  • Shijiazhuang high-level scientific and technological innovation and entrepreneurial talent program
  • Key technologies for ubiquitin-mediated protein-targeted degradation and the development of new drugs for tissue-targeted protein-targeted degradation in Class…

Zitieren

APA

Gao, Y., Li, X., Xin, C., Su, X., Ai, L., Zeng, J., Liu, S., & Wang, J. (2026). Pharmacokinetic Studies of a Novel c‐Met Targeting PROTAC Drug Candidate Using UPLC‐MS/MS Quantification Methods. Biopharmaceutics & Drug Disposition. https://doi.org/10.1002/bdd.70022

Vancouver

Gao Y, Li X, Xin C, Su X, Ai L, Zeng J, et al. Pharmacokinetic Studies of a Novel c‐Met Targeting PROTAC Drug Candidate Using UPLC‐MS/MS Quantification Methods. Biopharmaceutics & Drug Disposition. 2026. doi:10.1002/bdd.70022

BibTeX
@article{Gao2026,
  author = {Gao, Yan and Li, Xinyu and Xin, Chao and Su, Xiangdong and Ai, Lianfeng and Zeng, Jiangmeng and Liu, Shilin and Wang, Jinxu},
  title = {Pharmacokinetic Studies of a Novel c‐Met Targeting PROTAC Drug Candidate Using UPLC‐MS/MS Quantification Methods},
  journal = {Biopharmaceutics & Drug Disposition},
  year = {2026},
  doi = {10.1002/bdd.70022}
}
Kostenlos starten →